By Rumman Ahmed
BANGALORE--Indian drug maker Cipla Ltd. (500087.BY) Thursday
said it has lost an appeal in a U.S. court over a patent case
related to a pet drug.
A lower U.S. court had in June last year ordered the seizure of
pet drug PetArmor Plus made by Cipla and Velcera Inc. (VLCR) after
ruling the drug violated a patent held by Merial, a unit of French
giant Sanofi (SNY), covering Frontline Plus.
The U.S. court of appeals for the federal circuit in Washington
D.C. affirmed the order of the district court, Middle District of
Georgia, Cipla said in a statement to the stock exchanges.
The district court hasn't yet determined any financial
implication of the patent infringement, Cipla said.
Cipla, which was manufacturing the drug on behalf of Velcera,
said it was examining options for appealing against the latest
order.
Write to Rumman Ahmed at rumman.ahmed@dowjones.com